Moore Kuehn Encourages VBLT, RADI, TCRR, and BTE Investors to Contact Law Firm
07. März 2023 10:40 ET
|
Moore Kuehn
NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
Moore Kuehn Encourages PTRS, VBLT, INDT, and JNCE Investors to Contact Law Firm
27. Februar 2023 21:28 ET
|
Moore Kuehn
NEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
VBL Therapeutics Announces Appointment of Sam Backenroth as Chief Financial Officer and Establishes Operations in the United States
05. Oktober 2021 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel and NEW YORK, Oct. 05, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the appointment of Sam Backenroth as chief financial officer (CFO) effective...
VBL Therapeutics Announces Independent Data Safety Monitoring Committee Provides Clearance to Continue the OVAL Phase 3 Registration-Enabling Study of VB-111 in Ovarian Cancer
17. September 2021 07:00 ET
|
VBL Therapeutics
The OVAL Phase 3 clinical trial evaluating VB-111 in platinum-resistant ovarian cancer has recruited more than 320 patients (>80 %) to date;Remains on track to complete enrollment in 1Q22 TEL...
VBL Therapeutics to Present at Upcoming Conferences
10. September 2021 07:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, Sept. 10, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ: VBLT) today announced the Company will present in the following upcoming industry conferences: H.C. Wainwright 23rd...
VBL Therapeutics Announces Positive Outcome of the Interim Analysis in the OVAL Phase 3 Ovarian Cancer Pivotal Study
26. März 2020 07:54 ET
|
Vascular Biogenics Ltd.
OVAL independent Data Safety Monitoring Committee (DSMC) reviewed un-blinded data and determined that the study has met the interim pre-specified criterion, of an absolute percentage advantage of 10%...